1. Others
  2. Others

Ombrabulin hydrochloride (Synonyms: AVE8062; AVE8062A; AC7700; AVE-8062; AVE-8062A; AC-7700; AVE 8062; AVE 8062A; AC 7700)

Cat. No.: HY-18256
Handling Instructions

Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors.

For research use only. We do not sell to patients.
Ombrabulin hydrochloride Chemical Structure

Ombrabulin hydrochloride Chemical Structure

CAS No. : 253426-24-3

Size Price Stock Quantity
10 mM * 1 mL in DMSO $338 In-stock
1 mg $150 In-stock
5 mg $350 In-stock
10 mg $500 In-stock
50 mg $1500 In-stock
100 mg $2100 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Ombrabulin hydrochloride:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • References

Description

Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors. CA-4-P induces G2/M arrest, thus bringing about cell death by either mitotic catastrophe or apoptosis. Ombrabulin is a vascular disrupting agent. Target: Differently from CA-4-P, Ombrabulin does not act directly on the tumor vessels but instead causes constriction of the arterioles, resulting in complete downstream arrest of the blood flow and tumor. Recently, Ombrabulin in combination with cisplatin was used in a phase III clinical trial for patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy, significantly improving progression-free survival. However, this improvement was not clinically relevant, despite being statistically significant. [1] Ombrabulin disrupts the vasculature of established tumours and has shown preclinical synergistic anti-tumour activity when combined with cisplatin. The combination of ombrabulin and cisplatin significantly improved progression-free survival; however, it did not show a sufficient clinical benefit in patients with advanced soft-tissue sarcomas to support its use as a therapeutic option. Predictive biomarkers are needed for the rational clinical development of tumour vascular-disrupting drugs for soft-tissue sarcomas. [2]

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01907685 Sanofi Advanced Neoplastic Disease June 2006 Phase 1
NCT01063946 Sanofi Neoplasms, Malignant January 2010 Phase 1
NCT00968916 Sanofi Solid Tumor September 2009 Phase 1
NCT01193595 Sanofi Neoplasms, Malignant September 2010 Phase 1
NCT00719524 Sanofi Neoplasms July 2008 Phase 1
NCT01021150 Sanofi Neoplasms, Malignant March 2010 Phase 1
NCT01263886 Sanofi Non-small Cell Lung Cancer February 2011 Phase 2
NCT01095302 Sanofi Neoplasms, Malignant May 2010 Phase 1
NCT00699517 Sanofi Sarcoma June 2008 Phase 3
NCT01293630 Sanofi Advanced Solid Tumors January 2011 Phase 1
NCT01332656 Sanofi Ovarian Cancer Recurrent May 2011 Phase 2
View MoreCollapse
References
M.Wt

438.9

Formula

C₂₁H₂₇ClN₂O₆

CAS No.

253426-24-3

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO; Methanol: ≥ 30 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ombrabulin hydrochloride
Cat. No.:
HY-18256
Quantity: